SMS Pharmaceuticals Ltd (SMSPHARMA)
₹399.15
Mkt cap
₹3,727 Cr
P/E ratio
36.40
P/B
4.76
Div yield
0.10%
ROE
14.30%
ROCE
13.30%
EPS (TTM)
₹10.97
Book value
₹84
52W range
233–438
Sector
Healthcare
Price history
Previous close
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates. [1]
NSE SMSPHARMABSE 532815
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−8.93% from high₹399
₹233+71.18% from low₹438
Current
₹399.15
Prev close
₹397.80
Day
+0.34%
Price performance
1D
+0.34%
1W
+8.39%
1M
+7.33%
3M
+4.61%
6M
+3.39%
1Y
+70.10%
YTD
+22.34%
Financials
Revenue, profit & margin
P/E ratio
36.4×
SMSPHARMA is 4% above the sector median of 35.1×
SMSPHARMA36.4×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 | |
| Expenses | 109 | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 | |
| Operating Profit | 26 | 28 | 29 | 34 | 34 | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 | |
| OPM % | 19% | 17% | 18% | 14% | 20% | 16% | 19% | 16% | 20% | 20% | 21% | 17% | 20% | |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 | |
| Interest | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 | |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | |
| Profit before tax | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 | |
| Tax % | 31% | 21% | 26% | 26% | 25% | 29% | 24% | 30% | 23% | 26% | 26% | 23% | 26% | |
| Net Profit | 9 | 12 | 11 | 17 | 16 | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 | |
| EPS in Rs | 1.10 | 1.38 | 1.36 | 2.04 | 1.95 | 1.66 | 2.15 | 2.29 | 2.31 | 2.70 | 2.51 | 3.49 | 2.23 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.77% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 31 Jul '26◦ |
| Earnings day | −2.77% |
| +1 day | −2.78% |
| +5 days | −0.53% |
| +15 days | −5.30% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202668.07%Promoter
Promoters68.07%
FIIs0.65%0.34
DIIs2.83%0.19
Public28.45%0.15
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SMSPHARMA | ₹397.95 | 36.40 | 3,727 | 0.10% | 21 | +2.05% | 207 | +5.56% | 13.30% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts39
PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023TranscriptAug 2023PPTAug 2023RECAug 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 SepLetter To Shareholders Regarding Annual Report 4 Sep - 38th AGM on 29 Sep 2026; annual report dispatched; proposed dividend Rs 0.40 per share.Business Responsibility and Sustainability Reporting (BRSR) 4 Sep - SMS Pharmaceuticals filed BRSR for FY 2025-26, detailing ESG policies, workforce, compliance and sustainability initiatives.Notice Of 38Th Annual General Meeting To Be Held On 29Th September, 2026 4 SepReg. 34 (1) Annual Report. 4 Sep